Click on diagram to view fullscreen
Our proprietary protein aggregation technology: addressing unsolved challenges in drug discovery
A novel mechanism of action
Aelin Therapeutics has created an entirely new therapeutic modality with its proprietary Pept-in technology platform. Pept-ins are molecules capable of selectively driving the aggregation of specific target proteins, resulting in protein knock-down and/or proteostatic collapse of pathological cells. This enables functional inhibition of key proteins, blocking disease processes or resulting in cell death, granting Pept-ins a broad therapeutic potential.
Using aggregation prone regions as barcodes to target proteins
Aggregation of proteins in nature is driven by short amino acid stretches, called aggregation prone regions (APRs), within the protein sequence. Most proteins possess at least one APR, and most APRs are unique within the proteome. Pept-ins are designed based on the APR barcode to drive the aggregation of specific target proteins, resulting in protein knock-down and/or proteostatic collapse of pathological cells.
Unlocking the potential
The potential of the technology extends to all mammalian, bacterial and viral proteins. Aelin’s versatile in silico technology applies structural bioinformatics and machine learning to design sequence-specific, cell-permeable Pept-ins for an as yet unlimited range of disease indications.